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Purpose: Posaconazole is effective for the prophy-
laxis of invasive fungal infections (IFIs) in patients with
acute myeloid leukemia or myelodysplastic syndrome
during remission induction chemotherapy. However, a
cost–beneﬁt analysis of posaconazole versus ﬂucona-
zole or itraconazole has not been conducted in Korea.
Methods: We retrospectively reviewed data for all
consecutive patients who received primary antifungal
prophylaxis during remission induction chemotherapy in
our acute myeloid leukemia/myelodysplastic syndrome
cohort from December 2010 to November 2013. Patient
characteristics and factors known as a risk of IFI were
matched with propensity score analysis. We evaluated
the medical cost according to the prophylactic antifungal
agents (posaconazole vs ﬂuconazole/itraconazole), the
development of breakthrough IFIs, and survival status
after propensity score matching in a 1:1 ratio.
Findings: Of the 419 baseline patients, 100 patients
in each group were analyzed after matching. A
signiﬁcant decrease was found in the development of
breakthrough proven or probable IFIs (3.0% vs
14.0%; P ¼ 0.009) and the rate of empirical anti-
fungal therapy (EAFT) (12.0% vs 46.0%; Po 0.001)
in the posaconazole group. Total in-hospital medical
costs per patient were not statistically different be-
tween posaconazole and ﬂuconazole/itraconazole pro-
phylaxis. However, the daily medical cost was lower
for posaconazole prophylaxis, resulting in a total dailySeptember 2015cost savings of $72 (₩79,458) per patient (P ¼ 0.002).
In the cases of breakthrough proven/probable IFIs,
EAFT, and in-hospital deaths, the total medical costs
per patient were signiﬁcantly higher than in nonproven/
probable IFIs, non-EAFT, and in-hospital survivors, as
much as $7,916 (₩8,700,758), $4605 (₩5,062,529),
and $11,134 (₩12,238,422), respectively. Costs for the
antifungal agent used in targeted or empirical therapy
were lower in the posaconazole group, resulting in a
savings of $697 (₩766,347) per patient (P o 0.001).
Implications: Posaconazole appears to be cost
beneﬁcial for primary antifungal prophylaxis in
high-risk patients with hematologic malignancy, at a
single center, in Korea. Cost–beneﬁt is closely related
with clinical outcomes, including breakthrough IFI
development, EAFT, and survival status. (Clin Ther.
2015;37:2019–2027) & 2015 The Authors. Published
by Elsevier HS Journals, Inc.
Key words: acute myeloid leukemia, antibiotic
prophylaxis, cost–beneﬁt analysis, myelodysplastic
syndromes, posaconazole.2019
Clinical TherapeuticsINTRODUCTION
Invasive fungal infections (IFIs) still remain a cause of
morbidity and mortality in high-risk patients with
hematologic malignancies, associated with the pro-
longed neutropenia after myelosuppressive chemother-
apy or stem cell transplantation. The incidence rates of
IFIs varies from 4.7% to 13.1%, depending on the
underlying diseases and the treatment received.1,2
Because of the high mortality, 30% to 70% in IFIs,
fungal prophylaxis is considered a necessary treat-
ment.3,4 In the past, early-generation oral azoles such
as ﬂuconazole were used to reduce IFI, which have
limitations related to the spectrum of antifungal activity
and tolerability. Posaconazole, a newer azole that has a
broad spectrum, including Aspergillus spp and Candida
spp, has been used as a primary antifungal prophylaxis
according to the clinical trials in neutropenic patients
and stem cell transplant recipients with severe graft-
versus-host diseases.5,6
Studies on the effectiveness of antifungal prophy-
laxis were conducted in different clinical settings.7–10
Given the importance of local epidemiology in deter-
mining the strategy for prophylaxis, we previously
found that posaconazole was also effective for the
prophylaxis of IFIs in patients with acute myeloid
leukemia (AML) or myelodysplastic syndrome (MDS)
during remission induction chemotherapy at this
center.11 However, in this era of posaconazole
prophylaxis, there are concerns about the choice of
empirical antifungal agent, stemming from the broad
spectrum of posaconazole and the cost–beneﬁt of
prophylaxis because of the higher drug cost of
posaconazole compared with previous azoles. Data
for cost–beneﬁt analysis might differ according to the
health care cost system of each country or the clinical
outcomes of patients.
The aim of the present study was to evaluate the
cost–beneﬁt of primary antifungal prophylaxis with
posaconazole in patients with AML or MDS during
their induction or reinduction chemotherapy. Further,
both total medical costs and antifungal agent costs
were analyzed according to the breakthrough IFI
development and survival status.
METHODS
Patients and Study Design
We retrospectively reviewed all consecutive adult
patients who received antifungal prophylaxis during
induction or reinduction chemotherapy between2020December 2010 and November 2013 in the AML/
MDS cohort at the Catholic Blood and Marrow
Transplantation Center in Seoul St. Mary’s Hospital.
The hospital is a 1300-bed, university-afﬁliated tertiary
care center that performs 4350 stem cell transplanta-
tions annually. Use of posaconazole prophylaxis at this
center started in February 2013. Between December
2010 and January 2013, ﬂuconazole or itraconazole
was used as primary antifungal prophylaxis, whereas
posaconazole was used between February 2013 and
November 2013. Prophylaxis that consisted of 100 to
400 mg of oral ﬂuconazole per day, 2.5 mg/kg
itraconazole oral solution BID, or 200 mg of posaco-
nazole oral solution TID coadministered with fatty
meals was started 1 to 2 days before remission
induction chemotherapy and continued until absolute
neutrophil count recovered to 4500/mm3.12,13 No
other therapeutic strategies, except the antifungal pro-
phylaxis, were altered in this center during the study
period.
Eligible patients included those with AML or MDS,
who received antifungal prophylaxis during the re-
mission induction chemotherapy, and who were older
than 19 years of age. If a patient had repeated
remission induction chemotherapy, only the ﬁrst
episode was included. Patients who had a prior history
of IFIs within the past year, had received antifungal
prophylaxis for o7 days for any reason, or had
received empirical antifungal treatment (EAFT) at
the start of chemotherapy were excluded from the
analysis. The following data were collected: age, sex,
underlying hematologic diseases, comorbidities, labo-
ratory and radiologic results, type of anticancer
chemotherapy, antifungal prophylaxis, severity and
duration of neutropenia, empirical antifungal thera-
pies administered, the development of breakthrough
IFIs, and survival status. Medical costs were assessed
by analyzing the hospital’s computerized data by
intelligence support team of this hospital. The Institu-
tional Review Board of Seoul St. Mary’s Hospital
approved the research protocol with a waiver of
informed consent (KC14RISI0100).
Definitions
Categories of IFIs (proven, probable, and possible)
were deﬁned according to the revised deﬁnition of IFI
from the European Organization for the Research and
Treatment of Cancer/Mycoses Study Group.14 EAFT
was deﬁned as antifungal therapy in patients withVolume 37 Number 9
S.-Y. Cho et al.neutropenic fever and persistent or recurrent fever
despite broad-spectrum antibacterial agents and with-
out clinical or radiologic evidence of IFI.
Total medical cost was deﬁned as the sum of medical
cost and drug cost accrued during a whole hospitalized
period, paid both by patients and the government.
Antifungal agent cost was deﬁned as the drug cost for
all antifungal agents, which consisted of prophylactic,
empirical, targeted use for IFIs. The weighted average
cost was deﬁned as the average cost of each drug
weighted by market sales in Korea. In detail, weighted
average cost of drug A was calculated as a mean of drug
A formulated from various manufacturers, and the costs
of each formula were proportionally weighted accord-
ing to the sales volume in the previous year.
Medical Reimbursement System
Korea has a single-payer insurance system that is
run by the government. Persons can choose to join an
additional private insurance program; however, en-
rollment in the government-owned program is man-
datory. The reimbursement protocol of the mandatory
insurance system is as follows: The National Health
Insurance Service receives an insurance fee from
insured persons and from their company regularly,
and when insured persons visit a hospital or a
pharmacy, they pay only a small portion of the
medical costs (ie, copayment). At a later time, the
hospital or the pharmacy requests reimbursement
from the Health Insurance Review & Assessment for
the remaining portion of the medical cost. Special
beneﬁts are provided to patients with cancer. Korean
patients with cancer only pay 5% of the medical cost,
regardless of the type of medical center or cancer-
related items. Reimbursement does not apply to
foreign patients. Therefore, foreign patients were also
excluded from this study.
Costs Settings
Daily weighted average costs in US dollars for
antifungal prophylaxis was $3.2 to $8.4 (₩3,538–
9,186), $13.1 (₩14,375), and $66.4 (₩72,960), for
ﬂuconazole, itraconazole, and posaconazole, respec-
tively. The exchange rate was quoted on December
26, 2014 (1 US dollar ¼ 1,099.20 Korean won).
Statistical Analysis
To compare the medical costs of the different
periods, the propensity score-matching method wasSeptember 2015used to reduce bias, which acts as an external
confounding factor. This method is designed to
compare the 2 groups matched by individual charac-
teristics on the basis of the propensity score, a condi-
tional probability. Patients who used posaconazole or
ﬂuconazole/itraconazole were matched in a 1:1 ratio
by using the Greedy algorithm.15 In Greedy matching,
a subject in the posaconazole group was ﬁrst selected
at random. The subject in the ﬂuconazole/itraconazole
group whose propensity score was closest to that of a
randomly selected subject (from the posaconazole
group) was chosen for matching. This process is
then repeated until the subjects for whom matches
can be found has been exhausted from one group.
Selection of propensity score-matching variables
was performed as follows: (1) variables for calculating
propensity scores were suggested by the investigators;
(2) propensity scores were calculated with multivariate
logistic regression analysis with the types of antifungal
agents as the dependent variables; (3) 2 groups
(posaconazole and ﬂuconazole/itraconazole) were
matched in a 1:1 ratio using the probability of
propensity scores; (4) variables that were identical in
the propensity score between the 2 groups (P 4
0.999) were excluded; (5) the following ﬁnal variables
were selected: age, sex, underlying hematologic dis-
eases (AML or MDS), comorbidities (congestive heart
failure, myocardial infarction, peripheral vascular
disease, cerebrovascular accident, chronic obstructive
pulmonary disease, peptic ulcer disease, diabetes
mellitus, chronic kidney disease, solid tumor, liver
disease), chemotherapy (induction or reinduction che-
motherapy), nadir absolute neutrophil count, duration
of antifungal prophylaxis, prior azole exposure within
30 days before starting chemotherapy, exposure to
growth factor, total parenteral nutrition, performance
status, vital signs (systolic blood pressure, heart rate,
body temperature), urine output, and laboratory
results (hemoglobin, hematocrit, platelet, blood urea
nitrogen, creatinine, sodium, potassium, total biliru-
bin, albumin) of tests conducted on the day of starting
antifungal prophylaxis.
A χ2 test, Fisher exact test, or t test was performed
to assess differences between the 2 groups. Medical
cost data were all suggested as a geometric mean
(95% CI), because the cost data found nonnormal
distribution. Patients were stratiﬁed according to IFI
development, EAFT, and survival status. A 2-tailed
P value o 0.05 was considered signiﬁcant.2021
n = 419
exclusion.of
foreign patients
(n = 3)
posaconazole
(Feb. 2013 – Nov. 2013)
n = 135
propensity score matching in a 1:1 ratio
fluconazole/itraconazole
(Dec. 2010 – Jan. 2013)
n = 281
n = 100n = 100
n = 416
Figure 1. Study design.
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Of the 419 baseline patients, a total of 200 patients
were analyzed after matching. Three foreign patients,
for whom a different payment system was applied,
were excluded (Figure 1). No signiﬁcant differences
were found in baseline patient characteristics between
the 2 groups after propensity score matching (Table I).
As shown in Table II, the development of break-
through proven/probable IFIs was signiﬁcantly
decreased in the posaconazole group compared withTable I. Baseline characteristics after propensity score
itraconazole prophylaxis.
Characteristic
P
Age, mean  SD, y 4
Male sex, n (%)
Underlying disease, n (%)
AML
MDS
Chemotherapy, n (%)
Induction
Reinduction
Severe neutropenia (ANC o 100/mm3), n (%)
Duration of neutropenia, mean  SD, day 2
Duration of antifungal prophylaxis, mean  SD, day
Charlson comorbidity index, mean  SD
AML ¼ acute myeloid leukemia; ANC ¼ absolute neutrophil co
2022the ﬂuconazole/itraconazole group after propensity
score matching (3.0% vs 14.0%; P ¼ 0.009).
Possible IFIs and EAFT cases were also signiﬁcantly
decreased in the posaconazole group (20.0% vs
50.0%; P o 0.001). However, in-hospital mortality
was not signiﬁcantly different between the 2 groups
(10.0% vs 6.0%; P ¼ 0.297). In the posaconazole and
ﬂuconazole/itraconazole groups, total in-hospital
medical cost per patient was $23,237 (₩25,541,962;
95% CI, ₩23,928,164–₩27,264,601) and $25,635
(₩28,177,807; 95% CI, ₩26,138,403–₩30,247,106),
respectively (P ¼ 0.469). Length of hospital stay did
not statistically differ between the 2 groups (38.2 
9.7 vs 37.7  8.9 days; P = 0.726). However, the
daily medical cost for each patient was $624
(₩685,385; 95% CI, ₩656,456–₩715,589) under pos-
aconazole prophylaxis, which was signiﬁcantly lower
than $696 (₩764,843; 95% CI, ₩724,834–₩807,060)
of ﬂuconazole/itraconazole prophylaxis, resulting in a
total daily cost savings of $72 (₩79,458) (P ¼ 0.002).
As shown in Figure 2, total medical cost was higher
in patients who developed breakthrough IFIs or received
EAFT, regardless of which prophylactic antifungal agent
was administered. In the cases of breakthrough proven/
probable IFIs, total medical cost was $31,708 (₩34,
853,417; 95% CI, ₩29,576,788–₩41,071,420), whichmatching between posaconazole and fluconazole/
osaconazole
(n ¼ 100)
Fluconazole or itraconazole
(n ¼ 100) P
8.0  11.7 46.7  13.9 0.469
59 (59.0) 56 (56.0) 0.668
95 (95.0) 94 (94.0) 0.756
5 (5.0) 6 (6.0)
86 (86.0) 88 (88.0) 0.674
14 (14.0) 12 (12.0)
95 (95.0) 93 (93.0) 0.552
2.0  16.8 20.8  9.8 0.631
24.4  7.6 23.7  9.6 0.535
3.8  1.5 3.8  1.5 0.852
unt; MDS ¼ myelodysplastic syndrome.
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Table II. Comparison of clinical outcomes and total medical costs between posaconazole and fluconazole/
itraconazole prophylaxis. Length of stay and cost values are presented as mean (SD) and geometric
mean, respectively.
Proven/
probable
IFI, n (%)
Possible IFI/
EAFT, n (%)
In-hospital
mortality, n (%)
Length of
stay, day
Total medical
costs/admission
Total medical
costs/d
Posaconazole
(n ¼ 100)
3 (3.0) 20 (20.0) 10 (10.0) 38.2  9.7 $23,237 $624
Fluconazole/
itraconazole
(n ¼ 100)
14 (14.0) 51 (51.0) 6 (6.0) 37.7  8.9 $25,635 $696
Signiﬁcant
difference
–11 –31 — — — –$72
P 0.009 o0.001 0.297 0.726 0.469 0.002
EAFT ¼ empirical antifungal treatment; IFI ¼ invasive fungal infections.
S.-Y. Cho et al.was signiﬁcantly higher than $23,792 (₩26,152,659;
95% CI, ₩24,869,365–₩27,502,171) of non-IFIs (P ¼
0.001). Patients who received EAFT incurred more
costs than patients who did not ($27,735 [₩30,486,
737; 95% CI, ₩28,004,683–₩33,188,776] vs $23,130
[₩25,424,208; 95% CI, ₩23,990,159–26,943,979]; P ¼
0.001). In addition, total medical cost of the patients
who died in the hospital was higher ($34,773 [₩38,
222,598; 95% CI, ₩31,864,356–₩45,849,569]) than
that of survivors ($23,639 [₩25,984,176; 95% CI,
24,745,671–27,284,668]; P o 0.001).
A comparison of the total medical costs associated
with posaconazole and ﬂuconazole/itraconazole was
also conducted after stratiﬁcation by clinical condi-
tions (Table III). For breakthrough proven/probable
IFIs, total medical cost per patient did not differ
signiﬁcantly between the 2 groups. However,
posaconazole prophylaxis lowered the total medical
cost, with a cost savings of $3004 per patient in the
case of survivors during hospitalization (P ¼ 0.010).
Costs for antifungal agents are shown in Table IV.
The cost for antifungal agents per patient was higher
in the posaconazole group ($1918 [₩2,108,095; 95%
CI, ₩1,875,909–₩2,369,019] vs $491 [₩539,432;
95% CI, ₩390,313–₩745,524]; P o 0.001). How-
ever, antifungal costs used for treatment of IFIs and
EAFT were lower in the posaconazole group (IFI: $96
[₩105,161; 95% CI, ₩58,176–₩190,091] vs EAFT:September 2015$793 [₩871,508; 95% CI, ₩564,145–₩1,346,333];
P o 0.001). The cost for antifungal agents indicated
a cost savings of $495 per patient in the posaconazole
group, especially in patients in whom IFIs did not
occur. The overall cost–beneﬁt evaluated in all
scenarios are presented in Figure 3.
DISCUSSION
In this study, we evaluated the cost–beneﬁt of pos-
aconazole as a primary antifungal prophylaxis agent
in the AML/MDS cohort at a single center in Korea,
because cost–beneﬁt results might differ according to
the local epidemiology and health care cost system of
each country. We found that posaconazole is cost
beneﬁcial and effective in IFI prophylaxis, which is
closely related with the clinical outcome, including
breakthrough IFI development, rate of EAFT, and
survival status. Although daily antifungal agent cost
for prophylaxis is higher in the posaconazole group,
the cost savings of total daily medical costs were
observed in this study.
According to the results of this study, total medical
costs were higher in patients with proven/probable
IFIs and in-hospital death, regardless of the antifungal
agent used for prophylaxis. Therefore, cost data
should be considered in relation to the clinical out-
comes. The clinical importance of preventing and
treating IFIs is mainly based on the medical fatality2023
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Figure 2. Comparison of medical costs ac-
cording to the medical conditions.
*P o 0.05. EAFT ¼ empirical anti-
fungal therapy; IFI ¼ invasive fungal
infection.
Clinical Therapeuticsof these conditions. However, active preventive strat-
egies against IFIs are implemented because of IFIs’
high economic burden from a societal point of view in
times of budget restrictions. A German study also
reported that medical costs were higher in patients
with IFIs than without IFI (€51,517 and €30,454,
respectively).16 Currently, there is no debate about the
effectiveness of posaconazole in preventing IFIs on the
basis of the previous randomized controlled study in
patients with AML/MDS during remission induction
chemotherapy.5,7 However, study ﬁndings vary about
whether posaconazole prophylaxis has survival bene-
ﬁts. These contradictory results might be due to
differences in study design, sample size, and localTable III. Total medical costs stratified by development o
hospital mortality. Cost values are presented a
Posaconazole
(n ¼ 100)
Flucon
Cost n Cos
Proven/probable IFI
Yes $29,979 3 $32,0
No $23,055 97 $24,6
In-hospital death
Yes $35,731 10 $33,2
No $22,152 90 $25,1
IFI ¼ invasive fungal infection.
2024epidemiology.8–10,17 Although our results did not
indicate a survival beneﬁt in the posaconazole group
after propensity score matching, posaconazole pro-
phylaxis signiﬁcantly saved total medical costs of
$3004 per patient in the survivor group compared
with the nonsurvivor group. In addition, costs for
empirical antifungal therapy were also signiﬁcantly
saved in the posaconazole prophylaxis group. These
results suggest that the overall cost–beneﬁt of posaco-
nazole prophylaxis may be related to the efﬁcacy of
preventing IFIs and mortality rate.
The results of this study are consistent with data
from the United States, Canada, Switzerland, and
Spain.18–21 Data from the United States and Canada
indicate that posaconazole saves $600 and 0.07
life-years, and Canadian $4259 and 0.27 life-years
per patient, respectively, relative to ﬂuconazole/itra-
conazole in high-risk neutropenic patients.18,22 The
reported cost savings of posaconazole compared with
ﬂuconazole/itraconazole in Switzerland and Spain
were 1118 Swiss Francs and €1807 per patient,
respectively.20,21 Data from a single center in Aus-
tralia indicate that posaconazole saves AU$17,458
per patient over voriconazole.23 Most pharmaco-
economic studies thus far were conducted with the
same decision analytical model and the pivotal study
by Cornely et al.5,24 However, in the present study,
the results reﬂect a direct cost comparison between
posaconazole and ﬂuconazole/itraconazole by using
propensity score-matched analysis in a real-life
setting.f proven/probable invasive fungal infections and in-
s geometric mean.
azole/itraconazole
(n ¼ 100)
Cost savings by
posaconazole Pt n
91 14 — 0.749
53 86 — 0.190
34 6 — 0.696
56 94 –$3,004 0.010
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Table IV. Costs for antifungal agents stratified by the purpose. Cost values are presented as geometric mean.
Posaconazole
(n ¼ 100)
Fluconazole/itraconazole
(n ¼ 100)
Cost savings by
posaconazole PCost n Cost n
Total antifungal costs
(prophylaxis and treatment)*
$1,918 100 $491 100 $1,427 o0.001
Proven/probable IFI
Yes $3,158 3 $2,755 14 — 0.903
No $76 97 $571 86 –$495 o0.001
In-hospital death
Yes $2,673 10 $892 6 — 0.146
No $1,848 90 $472 94 $1,376 o0.001
Antifungal costs for treatment
(not, prophylaxis)†
$96 60 $793 67 –$697 o0.001
IFI ¼ invasive fungal infection.
*Median (range) for total antifungal costs are $1,792 ($110–$52,283) vs $201 ($62–$11,586) in posaconazole vs
ﬂuconazole/itraconazole prophylaxis (P o 0.001).
†Median (range) for antifungal costs except prophylaxis are $13 ($0–$49,163) vs $117 ($0–$11,494) in posaconazole vs
ﬂuconazole/itraconazole prophylaxis (P o 0.001).
S.-Y. Cho et al.This comparison of posaconazole and previous
azole prophylaxis has limitations that stem from
usage of periods in which prophylaxis strategy
changed. The study period of the posaconazole group
is shorter than that of previous azole prophylaxis
in this study. However, propensity score-matchedTotal medical costs in proven/probable IFI
Total medical costs in survivors*
Antifungal costs for treatment*
–$2,112
–$3,004
–$2,343
––3,000–4,000
Cost-ben
Antifungal costs*
Total daily medical costs*
Total medical costs
C
Figure 3. Tornado diagram of medical cost. Cost savings
compared with the fluconazole/itraconazole g
invasive fungal infection.
September 2015analysis was performed to compare antifungal agents
used during different periods. In addition, the
cost results were stratiﬁed according to clinical con-
ditions. This is the ﬁrst pharmacoeconomic study of
posaconazole prophylaxis conducted in an Asian
country.–$697
$1,427
–$72
0 4,0003,0002,0001,000–1,0002,000
efit of posaconazole prophylaxis ($/patient)
ost-saving Additional expenditure
or additional expenditure in the posaconazole group
roup according to each scenario. *P o 0.05. IFI ¼
2025
Clinical TherapeuticsCONCLUSION
Posaconazole appears to be more cost beneﬁcial than
ﬂuconazole/itraconazole for primary antifungal pro-
phylaxis in high-risk patients with hematologic malig-
nancy in Korea. The cost-saving results are closely
related to the development of breakthrough IFIs,
EAFT, and survival status.
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